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 Abstract.  This multi-center, randomized, parallel-group, double-blind, double-dummy study compared the efficacy 
and safety of chlorproguanil–dapsone–artesunate (CDA) and chlorproguanil–dapsone (CPG–DDS) in the treatment of 
falciparum malaria in Africa (Burkina Faso, Ghana, Mali, Nigeria). Six hundred patients (≥ 1 year of age) received CDA 
2.0/2.5/4.0 mg/kg, and 292 CPG–DDS 2.0/2.5 mg/kg, once daily for 3 days. Day 28 parasitologic cure rate (polymerase 
chain reaction [PCR]-corrected, per-protocol population) was 89.1% (416/467) for CDA, non-inferior but also superior 
to CPG–DDS, 83.0% (176/212) (treatment difference 6.1%; 95% confidence interval [CI] 0.3, 11.9). Glucose-6-phosphate 
dehydrogenase (G6PD) genotype was available for 844/892 (95%) patients. Occurrences of a composite hemoglobin 
safety endpoint (hemoglobin drop ≥ 40 g/L or ≥ 40% versus baseline, hemoglobin < 50 g/L, or blood transfusion) were 
CDA 13/44 (30%), CPG–DDS 7/24 (29%) in G6PD-deficient patients versus CDA 4/448 (< 1%), CPG–DDS 6/221 (3%) 
in G6PD-normal patients. No deaths occurred. CDA was more efficacious than CPG–DDS. However, the hemolytic 
potential in G6PD-deficient patients does not support further development of CDA. 
 INTRODUCTION 
 There were over 213 million clinical malaria episodes in sub-
Saharan Africa in 2006, causing over 800,000 deaths, mostly in 
children less than 5 years of age. 1 Although recent progress 
has been made in addressing the malaria burden in Africa, 2 
the efficacy of the most affordable anti-malarials has been 
compromised by the widespread emergence of  Plasmodium 
falciparum resistance to these agents. 1 
 Chlorproguanil–dapsone (CPG–DDS, Lapdap™) was devel-
oped through a public–private partnership as a low-cost, fixed-
dose combination for the treatment of uncomplicated malaria 
caused by  P. falciparum . 3 Studies of CPG–DDS efficacy and 
safety were encouraging and the file was approved by the UK 
Medicines and Healthcare Products Regulatory Agency in 
2003. In a pivotal study of 1,850 children, CPG–DDS had Day 14 
cure rates of 93–99% and was more effective than sulfadoxine–
pyrimethamine (SP) in three of five African countries. 4 
 Artemisinin derivatives are active against multidrug-resistant 
 P. falciparum , 5,6 rapidly reduce asexual parasitemia, 7,8 and 
are gametocytocidal, potentially reducing transmission. 9–13 
However, the short half-life of these agents precludes their 
use as monotherapy for uncomplicated malaria. To obtain the 
advantages of artemisinins, the World Health Organization 
(WHO) Global Malaria Program recommends artemisinin-
based combination therapy (ACT) for first-line treatment of 
 P. falciparum malaria in Africa. 14 Chlorproguanil–dapsone–
artesunate (CDA) was, therefore, developed as a low-cost, 
simple, fixed-dose ACT for use in Africa. Phase I and II stud-
ies were promising, with good efficacy and a safety profile con-
sistent with CPG–DDS. 15 
 Dapsone has been used extensively in leprosy and is known 
to reduce erythrocyte lifespan. This may be observed as hemo-
lysis and methemoglobinemia, though these have generally 
been considered mild and self limiting. A clinical safety trial 
of CPG–DDS suggested that the hemolytic effect of dapsone 
might be compounded in malaria patients with glucose-6-
phosphate dehydrogenase (G6PD) deficiency, though data 
were insufficient to fully assess the clinical significance of the 
findings. 4,16 G6PD deficiency is X-linked, therefore more com-
mon in males. 17 In hemizygous males, the most common African 
variant, G6PD A−, results in 10–15% of normal enzyme activ-
ity. 17 Female heterozygotes display mosaicism, with varying 
degrees of phenotypic enzyme activity. 18 When exposed to oxi-
dative stress, G6PD-deficient erythrocytes become damaged 
and are removed from circulation by the spleen. 17 Otherwise, 
G6PD-deficient patients are asymptomatic. 17 G6PD deficiency 
is common in populations exposed to malaria, and it may pro-
vide some protection from severe malaria. 17 
 This Phase III randomized clinical trial was designed to 
compare the efficacy and safety of CDA and CPG–DDS. A 
second Phase III trial of similar design compared CDA with 
artemether–lumefantrine (AL) and has been published else-
where. 19 Both trials used parasitologic cure (corrected for re-
infection) at Day 28 as the primary efficacy outcome, as this 
was the standard WHO-recommended efficacy outcome at 
the time the studies were designed. This study also thoroughly 
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investigated the possibility of G6PD-related hemolysis in 
patients treated with CDA and CPG–DDS. 
 METHODS 
 This randomized, parallel-group, double-blind, double-
dummy study was conducted between April 2006 and May 
2007 at seven sites in four African countries: Burkina Faso 
(Ouagadougou), Ghana (Kumasi), Mali (Doneguebougou 
and Banambani), and Nigeria (Ile-Ife, Jos, and Lagos). Ethical 
approval was obtained from each participating center’s eth-
ics committee or institutional review board and the WHO. 
Study procedures were conducted in accordance with Good 
Clinical Practice, applicable regulatory requirements, and 
the Declaration of Helsinki. The study was overseen by an 
Independent Data Monitoring Committee (IDMC), which 
appointed an independent end-point reviewer. Two IDMC 
interim safety analyses were planned. 
 Patients.  Eligible subjects were males or females, ≥ 1 year 
of age, with acute uncomplicated  P. falciparum malaria with 
2,000–200,000 parasites μL −1 . Inclusion criteria at screening 
were history of fever within 24 hr or tympanic temperature 
≥ 37.5°C; weight ≥ 7.5 kg; hemoglobin ≥ 70 g/L or hematocrit 
≥ 25% (if hemoglobin not available); ability and willingness to 
comply with the protocol. Written or oral witnessed consent 
was obtained from all study participants or their parents/
guardians. Assent was also required for subjects who were 
12–18 years of age. 
 Patients were excluded from the study if they had features 
of severe/complicated  P. falciparum malaria; evidence of con-
comitant infection (including  Plasmodium vivax ,  Plasmodium 
ovale , or  Plasmodium malariae ); any underlying disease that 
might compromise malaria diagnosis or evaluation of the 
response to study medication (including clinical symptoms of 
immunosuppression, tuberculosis, bacterial infection, cardiac 
or pulmonary disease); known hypersensitivity to study drugs 
or their excipients or allergy to biguanides, sulphones, sulpho-
namides, or artemisinin derivatives; known G6PD deficiency, 
methemoglobin-reductase deficiency, hemoglobin M or E, or 
porphyria; neonatal hyperbilirubinemia; malnutrition (defined 
as a weight:height ratio < −3 standard deviations or < 70% of 
the median of the National Center for Health Statistics/WHO 
normalized reference values); previously participated in the 
study; received any medications with hemolytic potential; or 
received recent anti-malarial therapy that would affect the 
efficacy evaluation or any investigational drug within 30 days 
or five half-lives (whichever longer). Female patients with a 
positive pregnancy test, or who refused consent for a preg-
nancy test, or who were breastfeeding were also excluded. 
 Objectives.  This study evaluated the efficacy of CDA versus 
CPG–DDS in uncomplicated  P. falciparum malaria, employing 
a non-inferiority comparison of parasitologic cure at Day 28 
corrected for re-infection. This study also sought to further 
qualify the safety of CDA versus CPG–DDS; a 2:1 CDA:CPG–
DDS randomization schedule was used to maximize the safety 
information obtained for CDA. 
 Study procedures.  Eligible subjects were randomized to 
CDA 2/2.5/4 mg/kg/day (GlaxoSmithKline, Greenford, UK) 
or CPG–DDS 2/2.5 mg/kg/day (GlaxoSmithKline), once daily 
for 3 days (Days 0, 1, and 2). For younger children, tablets were 
crushed and mixed with water just before administration. All 
therapy was directly observed. Patients vomiting within 30 min 
of dosing could be re-dosed. Vomiting again within 30 min of 
re-dosing led to administration of rescue medication (as per 
local clinical practice guidelines) and the subject was followed 
for safety assessment until Day 28. Enrolled patients were 
seen on Days 0, 1, 2, and 3 as outpatients, with clinic follow-up 
assessments at Days 7, 14, and 28, plus additional visits if 
thought necessary by the investigator or the patient. A home 
visit by a trained fieldworker was also conducted on Days 4, 
5, and 6 to check that the patient was well enough to remain 
at home. 
 Laboratory procedures.  Blood samples (∼10 μL) for par asite 
count assessment were taken by thumb prick at screen ing, before 
dosing on Days 0, 1, and 2 and on Days 3, 7, 14, and 28 plus any 
additional visits after Day 28. Thick films were Giemsa stained 
and parasites enumerated independently by two microscopists 
blinded to study treatment. Parasite densities were calculated 
according to WHO protocol WHO/HTM/RBM/2003.50. 20 Game -
tocyte densities were read from thick films at screening, Day 0 
(pre-dose) and Days 1, 2, 3, 7, 14, and 28 against a minimum of 
200 white blood cells (WBCs). 
 Two drops of blood were stored on filter paper for poly-
merase chain reaction (PCR) analysis of parasite genotype 
using  msp -1,  msp -2, and  glurp . 21,22 For patients with clinical or 
parasitologic failure after Day 7, parasite genotype at Day 0 
(pre-dose) versus Day of failure were compared in order to 
distinguish re-infection from recrudescence. Patients with 
indeterminate PCR results were considered to have missing 
data for that time point. 
 For G6PD genotype analysis, two drops of blood were col-
lected at Day 0 (pre-dose) onto pre-printed filter papers. The 
G6PD genotyping was performed by two central laboratories 
(Shoklo Malaria Research Unit, Mae Sot, Thailand and Kenya 
Medical Research Institute, Nairobi, Kenya). Following DNA 
extraction, PCR primers were used for amplification of loci 
at 376 A → G, 202 G → A, 542 G → T, 680 G → T, and 968 
T → C. 18,23–25 Amplicons were analyzed using restriction frag-
ment length polymerization, allowing recognition of wildtype 
G6PD B, and the common African mutations G6PD A, and 
the G6PD-deficient mutation A−. 18,23–25 The G6PD phenotype 
was determined at a central laboratory (Synexa, Cape Town, 
South Africa) from a Day 0 (pre-dose) blood sample using 
a commercial NADPH fluorescence test (Trinity Biotech, 
Wicklow, Ireland). Phenotypes were defined versus controls 
as normal, intermediate, and deficient for G6PD activity. The 
test distinguishes normal/intermediate G6PD enzyme activity 
from grossly G6PD-deficient samples. 
 Venous blood (2 mL) samples for hematology evaluations 
were taken at screening and at Days 1, 2, 3, 7, 14, and 28. Samples 
for clinical chemistry were taken at Days 0 (pre-dose), 3, 7, and 
28 and at Day 14 if Day 7 values were abnormal. 
 Efficacy assessment.  The primary efficacy endpoint, PCR-
corrected parasitologic cure rate, was defined as clearance 
of the initial malaria infection by Day 7 with the subject 
remaining infection free at Day 28. Day 14 parasitologic cure 
was defined as clearance of the initial malaria infection by 
Day 7, with the subject remaining infection-free at Day 14. The 
key secondary endpoint was the proportion of subjects with 
parasites remaining 24 hr after the first treatment dose. The 
reduction in parasite load versus baseline 24 hr after the first 
treatment dose was also calculated. 
 Other secondary endpoints assessed throughout the study 
were geometric mean asexual parasite densities; percent 
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reduction from baseline in parasite load; the proportion of 
subjects with gametocytes; gametocyte densities; presence 
(and severity) of the signs and symptoms of malaria; and body 
temperature. Derived fever clearance time was defined as 
the time (in hours) after the first dose of study medication to 
the time when body temperature decreased to < 37.5°C, and 
remained so for at least 48 hr. Adequate clinical and parasito-
logic response (ACPR) and PCR-corrected ACPR (ACPRp), 
excluding patients with new infections, were determined for 
Days 14 and 28. ACPR(p) was defined per WHO (2003) cri-
teria as, absence of parasitemia, irrespective of tympanic tem-
perature, without previous treatment failure. 20 
 Safety assessment.  Adverse events were recorded at screen-
ing, pre- and post-treatment on Day 0 and at all subsequent 
study visits and classified using the Medical Dictionaries for 
Regulatory Activities (MedDRA) coding system (Version 
10.1). Treatment-emergent adverse events were defined as 
any unfavorable and unintended sign, symptom, or disease 
(new or exacerbated) temporally associated with the use of 
a medicinal product. A serious adverse event was defined 
as resulting in death (or life-threatening); hospitalization or 
prolonged hospitalization; disability or incapacity; a congenital 
or birth defect; or was deemed serious by the investigator. 
Additional serious adverse event criteria were a decrease 
in hemoglobin of ≥ 40% from baseline; blood transfusion; a 
hemoglobin concentration of < 50 g/L; methemoglobin ≥ 20%; 
and methemoglobin ≥ 10–20% with clinical symptoms of 
methemoglobinemia. 
 Hemolytic effect was assessed using a composite “hemoglo-
bin safety” endpoint, defined prospectively as a hemoglobin 
decrease of ≥ 40 g/L or ≥ 40% versus baseline, or hemoglobin < 
50 g/L, or blood transfusion. 
 Sample size.  For the primary endpoint analysis, 420 evaluable 
subjects in the CDA group and 210 in the CPG–DDS group 
were needed to provide at least 90% power to show non-
inferiority of CDA to CPG–DDS with a one-sided hypothesis 
test and a 2.5% significance level. This calculation was based 
on a 7% non-inferiority margin, a 2:1 allocation ratio, and 93% 
efficacy for both treatments. Allowing for a 30% data loss, 
target randomization was 600 to CDA and 300 to CPG–DDS. 
 Randomization and blinding.  The computer-generated 
randomization schedule was provided by GlaxoSmithKline. 
Patients were allocated to a treatment group by the Reg-
istration and Medication Ordering System (RAMOS), accessed 
by telephone. In case of emergency, the investigator could 
unblind a subject’s treatment by RAMOS. Treatment groups 
were stratified according to age: 1 to < 5 years; 5 to < 15 
years; and ≥ 15 years to achieve at least 10% of target 
recruitment into each age category, the remaining allocation 
being unrestricted. All site investigators, laboratory personnel, 
and GlaxoSmithKline were blinded to patient allocation. 
Matching placebo was provided for both active treatments. 
 Statistical procedures.  The intent-to-treat (ITT) population 
included all randomized patients who received at least one 
dose of study medication. The per-protocol (PP) population 
was a sub-set of the ITT population, including those patients 
who did not violate the protocol to the extent that could 
impact the efficacy analysis. 
 In the ITT population, patients without a Day 28 parasito-
logic assessment were considered treatment failures for the 
primary endpoint. For the PP population, subjects with miss-
ing data were excluded from the relevant analyses. For both 
the PP and ITT analyses, patients with PCR-determined new 
infections were considered treatment successes at that time 
point. At subsequent time points, these patients were con-
sidered missing for the PP analysis and failures in the ITT 
analysis. 
 The null hypothesis was that CDA efficacy was inferior to 
that of CPG–DDS based on a primary endpoint of Day 28 
PCR-corrected parasitologic cure rate in the PP population. 
Two-sided 95% confidence intervals (CI) were calculated for 
this endpoint using the normal approximation to the bino-
mial distribution. Non-inferiority was shown if the lower 
limit of the 95% CI (CDA minus CPG–DDS) was equal to or 
greater than −7%. No adjustments for multiple comparisons 
were required. The effects of center, age group, and baseline 
parasitaemia count (categorized by ≤ 33% quantile, > 33%−
< 67% quantile, and ≥ 67% quantile) were studied using logis-
tic regression. The ITT population was used for a supportive 
analysis of the primary endpoint. A sensitivity analysis was 
performed on parasitologic cure for the Day 28 ITT popula-
tion using observed cases only, i.e. patients with missing data 
were excluded rather than treated as failures. 
 For the key secondary endpoint, the proportion of subjects 
with parasites present at 24 hr after the initial dose of study 
medication, treatment groups were compared using a χ 2 test 
at a two-sided 5% significance level using the ITT population. 
The ACPR and ACPRp were evaluated using the ITT and PP 
populations. The PP population was analyzed for reduction 
in parasite load versus baseline 24 hr after the first treatment 
dose. All other secondary efficacy endpoints and safety analy-
ses were analyzed using the ITT population. 
 Adverse events, serious adverse events, and laboratory 
abnormalities were tabulated by treatment group and sum-
marized using descriptive statistics. The frequency of serious 
adverse events, hematologic adverse events and hemoglobin 
data, and occurrences of the hemoglobin safety endpoint were 
analyzed by G6PD status, using the following terms: G6PD 
normal, G6PD heterozygous females, and G6PD deficient 
(A− hemizygous males plus A−/A− homozygous females). 
Occurrence of the hemoglobin safety composite endpoint was 
analyzed using logistic regression modeling to determine the 
contribution of G6PD genotype, weight, age, baseline hemo-
globin, baseline parasitaemia, and treatment. Hemoglobin 
changes from baseline to Day 7 were studied using analysis 
of variance, with terms for treatment, age, initial parasitemia, 
and actual dapsone dose (expressed as mg/kg), and expressed 
as treatment difference and 95% CI. Statistical analyses were 
performed by GlaxoSmithKline using SAS (version 8.2, SAS 
Institute Inc., Cary, NC ). 
 RESULTS 
 Patients.  The study population included 892 randomized 
subjects, all of whom received study treatment (ITT popu-
lation): 600 received CDA and 292 CPG–DDS ( Figure 1 ). 
The proportion of patients that withdrew prematurely from 
the study was similar between treatment groups ( Figure 1 ). 
Demographic and baseline clinical characteristics of the ITT 
population were similar for the two treatment groups ( Table 1 ). 
Overall, mean age (±SD) was 7.3 ± 9.4 years, mean weight 
20.8 ± 14.9 kg, 49% of patients were male, and all patients were 
black African. The G6PD genotype was available for 844/892 
(95%) patients, of whom 53/414 (13%) were A− hemizygous 
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males and 15/430 (3%) A−/A− homozygous females (i.e., 
G6PD deficient,  Table 2 ). Excluding patients with missing 
G6PD genotype data, Ile Ife had the highest proportion 
of G6PD-deficient subjects (11.3% [12/106]) and Jos the 
lowest (0/21). For hemizygous males, the highest proportion 
was 15.5% (27/174) from Ouagadougou and the lowest was Jos 
(0/10). Given this large range, not surprisingly the proportion 
of female genotypes was significantly different from expected 
values using the Hardy−Weinberg equation. G6PD phenotype 
was available for 747/892 (84%) patients ( Table 2 ). In male 
patients, concordance between G6PD genotype and phenotype 
(i.e., both were normal or both deficient) was 89% (321/361). 
Baseline characteristics of the PP population were similar to 
those of the ITT population. Treatment compliance (patients 
receiving all doses at the correct dose) was 96% (576/600) for 
CDA and 95% (276/292) for CPG–DDS. 
 Efficacy.  The PCR-corrected parasitologic cure at Day 28 
in the PP population (primary efficacy endpoint) was 89.1% 
for CDA versus 83.0% for CPG–DDS (treatment difference 
6.1%; 95% CI 0.3, 11.9) ( Table 3 ). Thus, CDA was both non-
inferior and superior to CPG–DDS for this endpoint. Logistic 
regression analysis of the primary endpoint found no effect of 
center, age, or baseline parasitemia, but the CPG–DDS:CDA 
odds ratio (OR) of 0.6 (95% CI 0.37, 0.97;  P = 0.037) for 
treatment success implied superiority for CDA. Outcomes for 
the ITT analysis were supportive of the PP analysis ( Table 3 ). 
A sensitivity analysis using observed data only found similar 
results, with PCR-corrected parasitologic cure rates of 438/498 
(88.0%) with CDA and 184/235 (78.3%) with CPG–DDS 
(treatment difference 9.7%; 95% CI 3.7, 15.6). Parasitologic 
cure at Day 14 was also non-inferior and superior with CDA 
versus CPG–DDS ( Table 3 ). 
 Asexual parasite count decreased rapidly from baseline 
in both treatment groups during the first 24 hr following the 
start of therapy. After 24 hr of therapy, for the ITT population, 
significantly fewer patients in the CDA group had parasites 
remaining (288/600 [48.0%]) versus the CPG–DDS group 
(259/292 [88.7%], treatment difference −40.7; 95% CI −46.1, 
−35.3;  P < 0.001) ( Figure 2A ). The mean reduction in para-
site load versus baseline (±SD) 24 hr after therapy start was 
99.6 ± 1.9% with CDA and 84.1 ± 84.4% for CPG–DDS in the 
PP population. 
 For those patients with a baseline temperature ≥ 37.5°C, in 
the CDA group, 243/394 (62%; 95% CI 59.6, 66.5) patients had 
fever clearance within 24 hr versus 61/199 (31%; 95% CI 24.3, 
37.1) in the CPG–DDS group. Mean body temperature nor-
malized more rapidly in the CDA versus CPG–DDS group 
( Figure 2B ). Mean (±SD) time to fever clearance was 33.1 ± 
20.1 hr in the CDA group and 45.7 ± 21.4 hr for CPG–DDS. 
 Figure 1.  Trial profile. NB: There may have been more than one 
reason for a patient’s withdrawal from the study or exclusion from the 
PP population. 
 Table 1 
 Demographic and baseline clinical characteristics (ITT population)* 
Characteristic CDA ( N = 600) CPG–DDS ( N = 292)
Female, n (%) 293 (49) 160 (55)
Age, years, mean (SD) [range]
1−< 5, n (%)
5−< 15, n (%)
≥ 15, n (%)
7.4 (9.5) [1–72]
305 (51)
234 (39)
61 (10)
7.1 (9.3) [1–72]
146 (50)
115 (39)
31 (11)
Weight, kg, mean (SD) [range] 21.0 (15.0) [8–112] 20.4 (14.9) [8–76]
Parasitemia, μL −1 , geometric mean [range] 21640 [988–200,000] 25573 [576–200,000]
Temperature, °C, mean (SD) [range] 37.9 (1.0) [35.0–40.7] 38.0 (1.0) [35.5–40.2]
Patients with fever (≥ 37.5°C), n (%) 394 (66) 199 (68)
Hemoglobin, g/L, mean (SD) [range] 104.0 (17.1) [45.0–158.0] 103.3 (16.2) [66.0–161.0]
1 to < 5 years 95.1 (14.2) [45.0–139.0] 94.6 (13.0) [66.0–126.0]
5 to < 15 years 109.6 (12.8) [70.0–142.0] 108.46 (11.8) [75.0–143.0]
≥ 15 years 127.0 (14.2) [93.0–158.0] 125.4 (15.1) [93.0–161.0]
Hematocrit, L, mean (SD) 0.314 (0.051) 0.313 (0.047)
Red blood cell count × 10 12 /L, mean (SD) 3.99 (0.63) 4.00 (0.57)
Platelet count × 10 9 /L, mean (SD) 202.4 (98.5) 208.9 (125.2)
White blood cell count × 10 9 /L, mean (SD) 9.75 (4.24) 10.51 (4.54)
 *  ITT = intent-to-treat; CDA = chlorproguanil–dapsone–artesunate; CPG–DDS = chlorproguanil–dapsone. 
973ANTIMALARIAL CLINICAL TRIAL
In most patients, other malaria signs and symptoms had 
resolved by Day 3 in both treatment groups, with no remark-
able differences between study therapies. 
 At baseline, gametocytes were present in 33/567 (6%) 
patients in the CDA group and 13/279 (4%) in the CPG–DDS 
group (ITT population). In the CDA group, the proportion of 
patients with gametocytes remained stable during treatment 
and declined during follow-up, whereas in the CPG–DDS 
group, the proportion increased during therapy and reached 
a maximum of 24% during follow-up (Day 7) ( Figure 2C ). 
Mean geometric gametocyte count was 1.2 μL −1 in both treat-
ment groups at baseline. In the CDA group, gametocyte count 
remained between 1.1−1.3 μL −1 throughout therapy and fol-
low-up. In the CPG–DDS group, gametocyte count increased 
to a maximum of 3.0 μL −1 at Day 7, decreasing to 1.4 μL −1 at 
Day 28 ( Figure 2C ). 
 Day 28 ACPRp was 89% with CDA and 79% with CPG–
DDS, with 2% and 11% early treatment failures, respectively 
( Table 4 ). By Day 28, 32% of patients receiving CDA and 30% 
receiving CPG–DDS in the PP population had experienced a 
re-infection ( Table 4 ). Results for the ITT population showed 
similar trends ( Table 4 ). 
 Adverse events.  Treatment-emergent adverse events were 
reported for 38% (227/600) of CDA-treated and 49% (144/292) 
of CPG–DDS-treated patients. The most frequently occurring 
(≥ 2% in either arm) adverse events included (CDA, CPG–
DDS): malaria (13%, 15%); pyrexia (6%, 10%); cough (4%, 4%); 
vomiting (3%, 5%); diarrhea (3%, 1%); pneumonia (3%, 2%); 
abdominal pain (1%, 3%); and respiratory tract infection 
(1%, 3%). Furthermore, there were 18 (3%) adverse events 
potentially related to oxidative hemolysis in the CDA group 
(14 anemia, four decreased hemoglobin) and 12 (4%) in the 
CPG–DDS group (nine anemia, two decreased hemoglobin, 
one intravascular hemolysis). 
 Twenty-one serious adverse events occurred in 16/600 (3%) 
patients in the CDA group and 13 occurred in 12/292 (4%) 
patients in CPG–DDS group. Anemia (CDA 11 cases, CPG–
DDS six cases) and decreased hemoglobin (CDA four cases, 
CPG–DDS two cases) were the most frequent serious adverse 
events. 
 There were no deaths in the study. Early withdrawals from 
the study for adverse events occurred in 3 (< 1%) patients 
receiving CDA and 6 (2%) receiving CPG–DDS. In all but 
one case, the reason for withdrawal was nausea/vomiting. The 
remaining case in the CPG–DDS group (G6PD genotype 
missing) had intravascular hemolysis and (unconfirmed) sep-
sis. All adverse events leading to withdrawal occurred during 
the dosing period (Days 0–2). 
 Hemoglobin safety.  The composite hemoglobin safety end-
point occurred most frequently in G6PD-deficient patients: 
13/44 (30%) in the CDA group and 7/24 (29%) in the CPG–
DDS group ( Table 5 ). Logistic regression analysis of potential 
risk factors for occurrences of the hemoglobin safety endpoint 
found a highly significant effect of G6PD deficiency versus 
G6PD normal: OR 40.0 (95% CI 16.1, 99.4;  P < 0.001). There 
was no difference between G6PD heterozygous versus G6PD 
normal, between the two study treatments, or for the other 
co-factors: weight, age, baseline hemoglobin, or parasitemia. 
 Five subjects required blood transfusions: two in the CDA 
group (one G6PD hemizygous A− male and one G6PD nor-
mal male) and three in the CPG–DDS group (one G6PD hem-
izygous A− male, one G6PD homozygous A−/A− female and 
one with unknown G6PD genotype and phenotype). 
 Hematologic laboratory data.  Mean hemoglobin concen-
tration decreased from baseline in both treatment groups, 
with no significant differences between treatment groups 
( Figure 3A ). For CDA, hemoglobin reached a nadir on Day 
7 of 93.2 g/L versus 94.0 g/L for CPG–DDS. For CPG–DDS, 
the minimum hemoglobin concentration occurred at Day 3; 
 Table 3 
 Parasitologic cure rates. PCR-corrected parasitologic cure at Day 28 (PP population) was the primary efficacy endpoint* 
 *  PCR = polymerase chain reaction; PP = per-protocol; ITT = intent-to-treat; CDA = chlorproguanil–dapsone–artesunate; CPG–DDS = chlorproguanil–dapsone; CI = confidence interval. 
 †  In the PP analysis, patients with missing data were excluded and patients with new infections (determined by PCR) were considered successes at the first time point that this outcome was 
recorded, but were excluded thereafter. 
 At Day 14, 16/553 patients were non-evaluable in the CDA group: 1 (0.2%) earlier new infection, 5 (0.9%) without PCR at Day 14, and 10 (1.8%) for “other” reasons. In the CPG–DDS group, 
10/259 patients were non-evaluable: 3 (1.2%) earlier new infection, 5 (1.9%) without PCR at Day 14, and 2 (0.8%) “other.” 
 At Day 28, 86/553 patients were non-evaluable in the CDA group: 62 (11.2%) earlier new infections, 4 (0.7%) without PCR at Day 28, and 16 (2.9) “other”. In the CPG–DDS group, 47/259 
patients were non-evaluable: 38 (14.7%) earlier new infections, 5 (1.9%) without PCR at Day 28, and 4 (1.5%) “other.” 
 ‡  In the ITT analysis, patients with missing data were treated as failures. Patients with new infections (determined by PCR) were considered successes at the first time point that this outcome 
was recorded and as failures thereafter. 
PP population† ITT population‡
Analysis Parasitologic cure rate, n/ N (%) CDA CPG–DDS CDA CPG–DDS
Day 14 PCR corrected 528/537 (98.3) 235/249 (94.4) 558/600 (93.0) 252/292 (86.3)
Treatment difference, % (95% CI) 3.9 (0.9, 7.0) 6.7 (2.3, 11.1)
Day 28 PCR corrected 416/467 (89.1) 176/212 (83.0) 438/600 (73.0) 184/292 (63.0)
Treatment difference, % (95% CI) 6.1 (0.3, 11.9) 10.0 (3.4, 16.6)
 Table 2 
 G6PD status by genotype and phenotype (ITT population)* 
Category, n (%)
Genotype/ 
phenotype† CDA CPG–DDS Total
 Males ( N = 307) ( N = 132) ( N = 439)
Missing 19 (6) 5 (4) 24 (5)
Genotype: 288 (93) 127 (96) 415 (95)
A 85 (30) 39 (31) 124 (30)
B 165 (57) 73 (57) 238 (57)
A− 38 (13) 15 (12) 53 (13)
 Females ( N = 293) ( N = 160) ( N = 453)
Missing 19 (6) 5 (3) 24 (5)
Genotype: 274 (94) 155 (97) 429 (95)
A/A 37 (14) 10 (6) 47 (11)
A/B 74 (27) 35 (23) 109 (25)
B/B 87 (32) 64 (41) 151 (35)
A/A− 16 (6) 11 (7) 27 (6)
B/A− 54 (20) 26 (17) 80 (19)
A−/A− 6 (2) 9 (6) 15 (3)
 All patients ( N = 600) ( N = 292) ( N = 892)
Missing 99 (17) 46 (16) 145 (16)
Phenotype: 501 (84) 246 (84) 747 (84)
Normal 406 (81) 202 (82) 608 (81)
Intermediate 47 (9) 26 (11) 73 (10)
Deficient 48 (10) 18 (7) 66 (9)
 *  ITT = intent-to-treat; CDA = chlorproguanil–dapsone–artesunate; CPG–DDS = 
chlorproguanil–dapsone. 
 †  Percentages for genotype and phenotype exclude missing data. 
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91.9 g/L versus 95.1 g/L for CDA. Hemoglobin concentrations 
recovered by Day 28 in both treatment groups ( Figure 3A ). 
 When assessed by G6PD status, there was no significant 
difference in hemoglobin concentrations over time between 
CDA and CPG–DDS in G6PD normal, heterozygous, or 
deficient patients ( Figure 3B , C, and D). In G6PD-deficient 
patients, the decrease in hemoglobin was greater than for 
G6PD-normal and heterozygous female patients ( Figure 3D ). 
In G6PD-deficient patients, the minimum hemoglobin con-
centration was at Day 7 for both treatment groups, 76.3 g/L 
(95% CI 71.3, 81.4) with CDA and 81.5 g/L (95% CI 72.4, 90.7) 
with CPG–DDS. 
 Adjustment for treatment, age, baseline parasitemia, center 
and actual dapsone dose showed a significantly greater mean 
decrease in hemoglobin at Day 7 with CDA (14.1 g/L) ver-
sus CPG–DDS (12.0 g/L; 95% CI 0.4, 3.9;  P = 0.016). At Day 
3, however, the mean hemoglobin decease was significantly 
greater with CPG–DDS (12.7 g/L) versus CDA (10.5 g/L; 
95% CI 1.0, 3.5;  P < 0.001). An analysis by G6PD genotype 
showed that these differences were only significant in G6PD-
normal patients (CDA − CPG–DDS): Day 3 (−1.77 g/L; 95% 
CI −3.0, −0.5;  P = 0.005) and Day 7 (1.83 g/L; 95% CI 0.1, 
3.5;  P = 0.033). There was no significant difference in adjusted 
mean change in hemoglobin versus baseline between the treat-
ment groups for G6PD-deficient patients or heterozygous 
females. 
 Decreases in hemoglobin of ≥ 20 g/L versus baseline 
occurred in 168/600 (28.0%) patients in the CDA group and 
98/292 (33.6%) in the CPG–DDS group overall. In the CDA 
group, a ≥ 20 g/L hemoglobin drop occurred in 96/448 (21%) 
G6PD-normal patients, 30/70 (43%) heterozygous females, 
and 30/44 (68%) G6PD-deficient patients. Corresponding 
results for CPG–DDS were 63/221 (29%), 18/37 (49%), and 
15/24 (63%), respectively. 
 There were no major differences between treatment groups 
for hematocrit or red blood cell (RBC) count. Platelet count 
improved for both treatment groups, with no remarkable dif-
ferences between groups. Decreases in WBC count were 
observed in both treatment groups following the start of dos-
ing and continuing through Day 28. 
 Clinical chemistry assessments. Alanine transaminase (ALT) 
elevations of clinical significance occurred in 18/600 (3%) 
patients in the CDA group and 4/292 (1%) in the CPG–DDS 
group. In most cases ALT elevations were transient and had 
resolved by Day 28. Two subjects with ALT elevations in the 
CDA group were diagnosed with hepatitis A. There were no 
other notable changes in clinical chemistry values. 
 DISCUSSION 
 Although we showed non-inferiority (and superiority) of 
CDA over CPG–DDS for the primary endpoint, the PCR-
corrected Day 28 parasitologic cure rates in the PP popu-
lation were lower than anticipated; 89.1% for CDA and 
83.0% for CPG–DDS. A companion Phase III trial con-
ducted at sites in Burkina Faso, Ghana, Kenya, Nigeria, 
and Tanzania reported Day 28 PCR-corrected parasito-
logic cure rates (PP population) of 94.1% (703/747) for 
CDA versus 97.4% (369/379) for the comparator AL. 19 In 
both studies, the cure rates for CDA fell short of the WHO-
recommended average cure rate of 95% for any new anti-
malarial medicine. 14 
 The lower than expected efficacy of CDA was probably not 
caused by drug resistance. Resistance to CPG–DDS is thought 
to require a quadruple  pfdhfr mutation at codons 108, 51, 59, 
and 164. 26 This mutation has been detected rarely in Africa, 
 Figure 2.  The effect of CDA and CPG–DDS on:  A , mean para-
site load (±interquartile range);  B , mean temperature (±95% CI); and 
 C , the percentage of patients that were gametocytemic (bars) and geo-
metric mean gametocyte count (lines). NB: error ranges are not shown 
for gametocyte data as lower and upper quartiles were all zero at every 
time point because over 75% of subjects had no gametocytes. 
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though there are reports from Kenya and at “hot-spots” in 
Uganda. 27,28 A limitation of both CDA Phase III studies was 
that drug resistance assays were not performed. 
 Two other recent studies also reported unsatisfactory effi-
cacy with CPG–DDS plus artesunate (A) given concomitantly. 
The Day 28 ACPRp with CPG–DDS+A at two sites in Rwanda 
was 71.9% (274/381) overall, versus 63.2% (247/391) for amo-
diaquine + SP. 29 A trial in Ghana reported PCR-corrected 
Day 28 parasitological and clinical cure rates (PP population) 
of 86.3% (138/160) for CPG–DDS + A, 86.2% (131/152) for 
AL, and 93.4% (141/151) for amodiaquine + A ( P = 0.08). 30 
Neither of these studies has reported  pfdhfr mutation fre-
quencies, though the authors of the Rwandan study state that 
a later analysis is planned. 29 
 There was no difference in re-infection rates between CDA 
and CPG–DDS. There was a relatively high intensity of trans-
mission in specific sites in our study. Overall, the re-infection 
rate was 32% (281/892), ranging from 45% (162/360) in Ouaga-
dougou to 0% (0/46) in Jos and (0/4) Lagos. These results were 
expected given the rapidly eliminated drug combinations; the 
parasitocidal activity of CPG–DDS is 3–10 days, depending on 
parasite strain. 31 In fact, the rationale for the CDA combina-
tion was to cure the initial infection, while avoiding prolonged 
drug concentrations that could select for resistant parasites 
after the elimination of artesunate. 
 Parasite clearance and fever resolution were more rapid 
with CDA versus CPG–DDS. There was also a lower propor-
tion of early treatment failure in the CDA group (2%) ver-
sus CPG–DDS (11%). Artemisinins are gameotocytocidal, 9 
and gametocytes were more effectively suppressed with 
CDA versus CPG–DDS. These observations clearly show the 
advantages of artesunate in the combination and support the 
current WHO recommendations for ACT use throughout 
Africa. 14 
 The major safety finding of this study concerned the hemo-
lytic effects of both treatments in G6PD-deficient patients. 
Overall, 53/414 (13%) males were G6PD hemizygous and 
15/430 (3%) females were G6PD homozygous (i.e., G6PD 
deficient). Furthermore, 107/453 (24%) females were G6PD 
heterozygous. The majority of malaria patients in Africa would 
be unaware of their G6PD status and G6PD testing is not gen-
erally available. 
 This study was not powered to compare hematologic 
safety in G6PD-deficient versus G6PD-normal individu-
als. However, we defined a composite hemoglobin safety 
endpoint to identify and group those drops in hemoglobin 
that would usually require medical intervention. Access to 
hospital and clinic facilities are often limited in sub-Saharan 
Africa, and any occurrence of the composite endpoint would 
represent an appreciable risk for an unfavorable patient 
outcome. Occurrences of the hemoglobin safety endpoint 
were 20/68 (29%) in G6PD-deficient patients versus 10/669 
(1.5%) in G6PD-normal patients overall. There was no 
difference in hemolytic risk between treatment groups. Logis-
tic regression identified G6PD deficiency versus G6PD 
normal as the only significant risk factor for the hemoglo-
bin safety endpoint (odds ratio 40.0; 95% CI 16.1, 99.4;  P < 
0.001). G6PD phenotyping detected all but one patient who 
experienced the hemoglobin safety endpoint; a heterozygous 
female. 
 The results for the companion Phase III trial of CDA ver-
sus AL also showed an unacceptable risk of hemolytic adverse 
events for G6PD-deficient patients in the CDA arm. 19 In that 
study, 28/80 (35%) of G6PD-deficient patients in the CDA arm 
had an occurrence of the hemoglobin safety endpoint versus 
0/36 with AL. The main risk factors associated with the hemo-
globin safety endpoint were G6PD deficient versus G6PD 
normal (OR 16.3; 95% CI 8.6, 31.2) and CDA treatment ver-
sus AL (OR 5.1; 95% CI 2.1, 12.4). 
 Table 4 
 Adequate clinical and parasitologic response uncorrected (ACPR), and PCR-corrected (ACPRp)* 
 * ACPR = adequate clinical and parasitologic response; PCR = polymerase chain reaction; PP = per-protocol; ITT = intent-to-treat; CDA = chlorproguanil–dapsone–artesunate; CPG–DDS = 
chlorproguanil–dapsone. 
 †  For the PP population, patients with missing data or indeterminate results were excluded—the denominator shows the number of evaluable patients. For the ITT population, patients with miss-
ing or indeterminate PCR results were treated as failures. For ACPRp, in the PP and ITT analysis, patients with new infections were considered successes at that time point. However, at subsequent 
time points, the PP analyses considered these patients as missing and the ITT analysis assumed that they were failures. 
 ‡  Early treatment failure rates are the same at Day 28. 
 § ACPRp is corrected for reinfection. 
PP population† ITT population†
Analysis Outcome, n/ N (%) CDA CPG–DDS CDA ( N = 600) CPG–DDS ( N = 292)
Day 14 Early treatment failure‡ 11/548 (2) 27/257 (11) 24 (4) 39 (13)
Late clinical failure 1/546 (< 1) 2/258 (< 1) 8 (1) 3 (1)
Late parasitological failure 18/548 (3) 12/257 (5) 16 (3) 18 (6)
ACPR 513/543 (94) 215/256 (84) 552 (92) 232 (79)
ACPRp§ 524/543 (97) 219/256 (86) 563 (94) 237 (81)
Day 28 Late clinical failure 65/551 (12) 36/258 (14) 79 (13) 45 (15)
Late parasitological failure 157/548 (29) 67/257 (26) 165 (28) 75 (26)
ACPR 311/544 (57) 126/256 (49) 332 (55) 133 (46)
ACPRp§ 484/544 (89) 201/256 (79) 519 (87) 217 (74)
 Table 5 
 Hemoglobin safety composite endpoint occurrences (hemoglobin 
decrease of ≥ 40 g/L or ≥ 40% vs. baseline or hemoglobin < 50 g/L 
or blood transfusion) by G6PD genotype and phenotype (ITT 
population)* 
Population, n/ N (%) CDA ( N = 600) CPG–DDS ( N = 292)
G6PD genotype
Normal 4/448 (< 1) 6/221 (3)
Female heterozygous 0/70 1/37 (3)
G6PD deficient† 13/44 (30) 7/24 (29)
Missing 3/38 (8) 1/10 (10)
G6PD phenotype
Normal 3/406 (< 1) 5/202 (2)
Intermediate 1/47 (2) 1/26 (4)
Deficient 11/48 (23) 5/18 (28)
Missing 5/99 (5) 4/46 (9)
Total 20/600 (3) 15/292 (5)
 *  ITT = intent-to-treat; CDA = chlorproguanil–dapsone–artesunate; CPG–DDS = 
chlorproguanil–dapsone 
 †  Deficient is male hemizygous and female homozygous for G6PD A−. 
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 CDA was envisaged as an affordable artemisinin-based com-
bination therapy for use in Africa. However, given the high 
prevalence of G6PD-deficiency in sub-Saharan Africa, and 
the current availability of alternative ACTs, the risk:benefit 
balance of treating mild-to-moderate malaria with CDA in 
this setting would be unacceptable. Consequently, the CDA 
development program has been discontinued and CPG–DDS 
licenses have been withdrawn voluntarily. 
 Previous studies of CPG–DDS did not prospectively include 
G6PD genotyping for all subjects. The major CPG–DDS safety 
study by Alloueche and others 4 retrospectively genotyped 
some patients with hemoglobin drops of ≥ 20 g/L versus base-
line and compared them to controls. However, because of sam-
ple bias and hemoglobin readings not being collected at the 
appropriate time points, the hemolytic potential of CPG–DDS 
in G6PD-deficient patients could not be fully determined. 16 A 
recent open randomized trial in patients with uncomplicated 
 P. falciparum conducted in Rwanda, compared CPG−DDS + A 
with amodiaquine + SP and included a secondary analysis for 
the risk of severe anemia in patients with G6PD deficiency. 29,32 
Results were analyzed using mean packed cell volume (PCV) 
and so cannot be compared directly with the results reported 
here. However, as in the current study of the CDA fixed-dose 
combination, CPG–DDS + A was associated with increased 
hemolysis and a greater risk of blood transfusion in G6PD-
deficient versus G6PD-normal patients. 32 
 There were some limitations in the hematologic data col-
lected during this study. Methemoglobin levels were measured 
for only five patients in each treatment arm at screening. A 
clinic-based methemoglobin test was not available at the start 
of the study and data could not be routinely collected at the 
study sites. Reticulocyte absolute values and percentages were 
collected, but methods were not automated and there was no 
quality control process. Meaningful analysis of these data was 
not possible and they are not presented. Unfortunately, delays 
in reporting G6PD phenotype and genotype meant that these 
data were not available to the IDMC until after recruitment 
was complete and so could not be linked to hematological 
adverse events. 
 We believe this to be the first Phase III clinical trial program 
in any field to prospectively include G6PD genotyping. This 
work answers the important question of whether the G6PD-
related hemolysis observed with CPG–DDS is exacerbated 
in the presence of artesunate. In fact, the hemolytic adverse 
effects of CDA and CPG–DDS in this work are very simi-
lar overall and in the G6PD-deficient sub-population. This is 
reassuring regarding the use of artesunate in other combina-
tions, but raises questions regarding the risk:benefit of other 
potentially oxidative agents when used in G6PD-deficient 
populations. 
 Received June 22, 2009.  Accepted for publication August 17, 2009. 
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 Figure 3.  Mean hemoglobin (±95% CI) over time with CDA and CPG–DDS in the intent-to-treat (ITT) population for:  A , all patients; and by 
G6PD genotype:  B , normal;  C , female heterozygous; and  D , deficient (male hemizygous and female homozygous). Day 0 are screening (baseline) 
values. 
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